Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway.

Clinical and translational medicine - 1 Feb 2025

He Chunxiao, Yu Jiaying, Mao Shuang, Yang Shaohua, Jiang Xianming, Huang Lei, Li Mingzhe, He Yulong, Zhang Xinhua, Xiang Xi

Abstract excerpt

BACKGROUND: Most gastrointestinal stromal tumours (GISTs) are driven by KIT proto-oncogene, receptor tyrosine kinase (KIT). Targeted treatment with imatinib has been successful in primary GIST patients. However, resistance and relapse gradually develop due to secondary KIT mutations. Identifying novel therapeutic targets for advanced GIST with KIT mutants is critical. METHODS: Clustered regularly interspaced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin D1
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Glycogen Synthase Kinase 3 beta

Share to Imatinib Mesylate

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 39981588
DOI: 10.1002/ctm2.70231
PMCID: PMC11843164

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway.PMID 39981588Read ↗

Developing SHP2-based combination therapy for KRAS-amplified cancer.Semantic proximity Read ↗

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Semantic proximity Read ↗

Biological and therapeutic implications of RKIP in Gastrointestinal Stromal Tumor (GIST): an integrated transcriptomic and proteomic analysisSemantic proximity Read ↗

New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal TumorSemantic proximity Read ↗

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.Semantic proximity Read ↗

SOCS2 inhibits the tumorigenesis of GISTs and increases the sensitivity of GISTs to imatinib by suppression of KIT activation.Semantic proximity Read ↗

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage StrategySemantic proximity Read ↗

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.Semantic proximity Read ↗

THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumoursSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.